Most Read Stories
ASCO Clinical Practice Guideline Update: Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
PROSPER: Enzalutamide Prolongs Metastasis-Free Survival in Nonmetastatic Castration-Resistant Prostate Cancer
PDL1 Amplification in Solid Tumors
FDA Approves Nivolumab Plus Low-Dose Ipilimumab for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer
Raising Awareness of the Financial Impact of Cancer on Young Adult Survivors
FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer
Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease
AR-V7 as Marker for Taxane vs Androgen Receptor Inhibitor Treatment in Castration-Resistant Prostate Cancer
Pazopanib Plus Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
IMpassion130: Atezolizumab Plus Nab-Paclitaxel in Metastatic or Locally Advanced Triple-Negative Breast Cancer
KEYNOTE-407: Pembrolizumab Plus Chemotherapy Benefits Response, Survival in Squamous NSCLC
Body Mass Index, Age, and Premenopausal Breast Cancer Risk
Addition of Systemic Therapy to Involved-Field Radiotherapy in Early-Stage Follicular Lymphoma
Pooled Study Analysis Explores the Use of CDK4/6 Inhibitors in Metastatic Breast Cancer
Human Papillomavirus Vaccine in Cutaneous Basaloid Squamous Cell Carcinomas
Ensuring High-Quality Oncology Care for Patients With Intellectual Disabilities
First-Line Treatment With Checkpoint Inhibitors in Patients With Melanoma Brain Metastases
Intratumoral Recombinant Poliovirus in Grade IV Glioblastoma
More Evidence of Benefit With Immunotherapy and Chemotherapy in Nonsquamous Non–Small Cell Lung Cancer
FDA Accepts sBLA for Pembrolizumab in Combination With Chemotherapy as First-Line Treatment for Metastatic Squamous NSCLC

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.